1835 ET - Hims & Hers Health says it will stop offering compounded semaglutide, a version of the active ingredient in weight-loss drugs Wegovy and Ozempic, after the first quarter. The stoppage comes after the FDA last week determined that shortages of the drugs had been resolved. CEO Andrew Dudum says on a call with analysts that the company will begin notifying customers of the stop in the coming weeks. "I would suspect, you know, just being very direct, that a lot of those patients will try to go into the open market and try to secure a branded option in some form factor," he says, though he adds that the company will continue to offer other forms of weight-loss drugs on its platform. Shares fall 18% in after-hours trading. (connor.hart@wsj.com)
(END) Dow Jones Newswires
February 24, 2025 18:35 ET (23:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。